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EDITORIAL
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A number of authors have reviewed the epidemiology,
diagnosis, and treatment of uveitis in children and
adolescents.1–16 Data from both clinic- and population-
based surveys have shown that children and adolescents
develop ocular inflammation less frequently than
adults.17,18 Children and adolescents with uveitis are
more likely to have severe, chronic inflammation how-
ever, and therefore tend to be at higher risk of developing
ocular complications and permanent vision loss19,20—
consequences that can impact vision-related quality of
life and function for many future decades.21 Moreover,
while the etiology of the inflammation remains indeter-
minate, referred to as idiopathic by some or undifferen-
tiated by others, in a sizable minority of patients,
identified causes of uveitis clearly differ in young
patients compared with adults. By definition, juvenile
idiopathic arthritis (JIA)22–28 presents in children, for
example, and adolescents are much more likely to
develop intermediate uveitis/pars planitis29–31 or tubu-
lointerstitial nephritis with uveitis (TINU)32–34 than are
either the middle-aged or elderly. Children also develop
a disproportionate burden of infectious uveitis,19,35 much
of which is posterior, including toxoplasmic retinochor-
oiditis, necrotizing herpetic retinitis, toxocariasis, and
both Bartonella henselae and nematode-associated neuror-
etinitis. In infants, congenital toxoplasmosis, rubella,
cytomegalovirus, and Herpes simplex virus (TORCH)-
related syndromes need to be considered.36–38 Similarly,
otherwise-uncommon uveitic masquerade syndromes
also occur in children, such as retinoblastoma, juvenile
xanthogranuloma,39 and a recently reported genetically
determined retinal dystrophy masquerading as severe
intermediate uveitis.40 Unique treatment issues, particu-
larly the management of cataracts to minimize the risk of
amblyopia41,42 and judicious use of systemic
corticosteroids to avoid growth retardation, are also
encountered.43,44 Three reviews,34,45,46 seven original
articles,47–53 and two letters54,55 in this issue of Ocular
Immunology & Inflammation (OII) address important
aspects of the causes, management, complications, and
outcomes of uveitis in children and adolescents.
Aguilar et al.34 described a 62-year-old woman
from Bogotá, Colombia, who developed histopatholo-
gically confirmed TINU, an uncommon condition in
the elderly, in the setting of relapsing polychoondritis
—an association not reported previously. As with
many patients with TINU, the patient had mild, bilat-
eral, non-granulomatous, anterior uveitis, ultimately
requiring the administration of a systemic immuno-
suppressive agent, mycophenolate mofetil, to achieve
lasting control. As summarized by the authors34 and
others,56–59 TINU constitutes 1–2% of patients seen at
uveitis referral centers, and is particularly common in
children and adolescents who develop bilateral ante-
rior uveitis of sudden onset. Frequent systemic symp-
toms include fever, fatigue or malaise, and abdominal
pain. Both systemic symptoms and the nephritis typi-
cally precede the uveitis, but in about 20% of cases,
the uveitis occurs first and in 15%, they occur concur-
rently. While definitive diagnosis requires histopatho-
logic confirmation of acute interstitial nephritis (AIN),
renal biopsy is often difficult to justify in the absence
of acute signs or symptoms suggestive of AIN, parti-
cularly in children. A presumptive diagnosis of AIN
may be made in patients with: (1) abnormal renal
function, defined as elevated creatinine or creatinine
clearance; (2) abnormal findings on urinalysis consis-
tent with AIN; and (3) a history of acute systemic
illness lasting for at least 2 weeks and characterized
by typical signs, symptoms, and laboratory findings.57
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In practice, many tend to order urinalysis with a
specific request for a urinary β2-microglobulin level
and a serum creatinine level when considering the
diagnosis of TINU in patients with uveitis, since
together these simple screening tests have been
shown to be both sensitive and predictive.60
Chronic or recurrent inflammation develops in
≥50% of cases, often requiring long-term immuno-
suppression. The prognosis tends to be good with
prompt and adequate therapy. In addition to
TINU, the main diagnoses to consider in children
and adolescents with both uveitis and renal
disease include systemic lupus erythematosus, sar-
coidosis, granulomatosis with polyangiitis, and
Sjögren syndrome.60
Petrushkin et al.45 provided a systematic overview
of the pathogenesis, clinical features, and treatment of
familial Mediterranean fever (FMF), a recessively
inherited, multisystem, autoinflammatory disease
that affects children from the Mediterranean basin—
most notably those with Turkish, Armenian, Arabic,
and Sephardic Jewish ancestry. Genetic polymorph-
isms associated with FMF occur in the MEFV
(Mediterranean fever) gene, located on chromosome
16 and now known to code for pyrin—a 781 amino
acid protein with incompletely understood roles in
the regulation of the cellular cytoskeleton, apoptosis,
and activation of intracellular pathways involved in
inflammatory cytokine signaling. Approximately 300
different polymorphisms have been described, many
resulting in phenotypically diverse presentations.
Roughly half of all FMF patients will experience a
neuropsychiatric prodrome 1–2 days prior to an
attack—typically anxiety or depression. A vast major-
ity of patients will then develop high fever and gen-
eralized abdominal pain. Many also develop
arthralgias and/or pleuritis, which is typically unilat-
eral and may be mistaken for pneumonia. Children
who develop episodes of joint pain and swelling may
be misdiagnosed as having acute rheumatic fever or
JIA. Pericarditis and erysipelas-like dermatitis have
also been described, but are uncommon.
Amyloidosis occurs in a minority of patients, but
can be severe, resulting in frank renal failure. As
discussed by Petrushkin et al.,45 ophthalmic manifes-
tations are generally quite rare, but isolated case
reports have described episcleritis, scleritis, anterior,
intermediate, posterior, and panuveitis—including
one case with unilateral frosted branch angiitis.
Subretinal drusenoid deposits have been described
most frequently, but mostly in the older literature,
prior to the advent of modern multimodal imaging.
Abnormal or delayed corneal wound healing has
been described in several patients. Oral colchicine
constitutes the mainstay of therapy and is at least
partially effective in the vast majority of patients.
Inhibitors of both interleukin-1 (IL-1) and tumor
necrosis factor (TNF) signaling have been used with
good therapeutic results in patients who were either
refractory or incompletely responsive to colchicine.
Alim et al.47 used spectral domain-optical coher-
ence tomography (SD-OCT) to measure the thickness
of the peripapillary retinal nerve fiber layer (RNFL)
and retinal ganglion cell-inner plexiform layer
(GCIPL) in the eyes of 39 patients with FMF without
ocular complaints, and 36 age- and gender-matched
healthy control subjects. All patients were Turkish
with a mean age of approximately 10 years. The
authors identified no statistically significant differ-
ences in mean RNFL, mean GCIPL, or mean macula
thickness between FMF patients versus controls.
Further analysis of the results requested in a letter
by Uzun et al.54 revealed no effect of either refractive
error or the presence or absence of the M694V
mutation.55 These results were generally consistent
with those reported by Erdurmuş et al.61 and were
perhaps not unsurprising, given how uncommon ret-
inal findings are in patients with FMF.
Abu Samra et al.46 reviewed the occurrence, cause,
and management of ocular complications in patients
with JIA. The authors reminded us of the often asymp-
tomatic nature of the uveitis and thus the importance
of scheduled ophthalmic screening examinations.
Guidelines formulated in 2006 by the American
Academy of Pediatrics are directed by JIA subgroup,
ANA status, age at onset, and disease duration.
Patients who have oligoarticular JIA, are ANA-
positive, were relatively young at disease onset, and
who have had JIA for a relatively short time are recom-
mended for screening every 3 months.62,63 They also
outlined their “step-ladder” approach to therapy,
which involves topical corticosteroids initially, then
oral non-steroidal anti-inflammatory drugs (NSAIDs),
followed by immunomodulatory therapy (IMT) – typi-
cally methotrexate. Children requiring a second agent
are usually administered adalimumab at their center.
The authors succinctly summarized the common ocu-
lar complications of JIA, including band keratopathy,
cataract, macular edema, epiretinal membrane forma-
tion, and glaucomatous optic neuropathy. While the
reported prevalence of such complications from refer-
ral centers has varied dramatically, depending most
directly on disease duration, treatment patterns, and
follow-up, the largest study of the ocular complica-
tions of JIA was performed by The Systemic
Immunosuppressive Therapy for Eye Diseases (SITE)
Cohort Study research group, a five-center consortium
that reported on 327 patients (596 affected eyes) with
JIA-associated uveitis.64 In this multicenter study,
vision loss ≤20/50 and ≤20/200 occurred in 40.3% and
24.2% of eyes, respectively. The frequency per eye of
any complication over the variable course of follow-up
(0–24 years; median 2.62 years) was 60.2% (0.15 per
eye-year, EY). Reported individual complications
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included posterior synechiae (29.0%; 0.10 per EY),
band keratopathy (34.1%; 0.14 per EY), macular
edema (5.4%; 0.04 per EY), epiretinal membrane for-
mation (4.9%; 0.03 per EY), hypotony <5 mmHg (4.5%;
0.05 per EY), and ocular hypertension ≥21 mmHg
(14.8%; 0.10 per EY). The research group also showed
that increased uveitis activity was associated with a
significantly increased risk of vision loss, while use of
IMTwas associated with a significantly reduced risk of
vision loss. From these findings, the authors concluded
that control of inflammation and appropriate use of
immunosuppression are important contributors to
improved outcomes of patients with JIA-related uvei-
tis. While the frequency of cataract was not provided,
an earlier study of a subgroup of 75 (22.9%) of these
patients (132 affected eyes; 22.1%) from theWilmer Eye
Institute reported a frequency of cataract of 22.5%
(0.04 per EY).65 Of these various complications, man-
agement of JIA-associated cataract is perhaps the most
controversial – specifically the choice of anterior versus
posterior, pars plana approach and whether an intrao-
cular lens should be implanted. Abu Samra et al.46
recommended an anterior approach with standard
intraocular lens implant (IOL) placement in eyes with
well-controlled, inactive uveitis, versus performing a
pars plana lensectomy/vitrectomy without IOL place-
ment in eyes with more difficult to control inflamma-
tion, particularly when clinically significant vitreous
inflammation is present. Phatak et al.41 provided a
thoughtful recent review of this specific topic, and
advised specifically against placement of an IOL in
very young children, or in eyes with active uveitis,
despite maximal medication, with hypotony, or with
rubeosis. They also cautioned against IOL implanta-
tion in patients with uveitis of indeterminate cause,
and when there is a history of IOL-related complica-
tions having occurred in the fellow eye. Sijssens et al.66
showed that early treatment with an antimetabolite,
such as methotrexate (MTX), was associated with a
mean delay in the development of cataract requiring
surgery of 3.5 years, which might positively influence
the surgery outcomes.
Kolomeyer et al.48 described the clinical findings and
outcomes in a series of 82 patients (147 eyes) with JIA-
associated uveitis. Patients were seen over 11 years at
two referral centers: one in New Jersey, USA, and
the second in Milan, Italy. All patients were followed
at least 2 months. Overall, the frequencies of specific
JIA-associated ocular complications were comparable
with, although slightly higher than, those reported by
the SITE research group. A multivariate analysis of out-
comes using generalized estimating equations identi-
fied older age at onset, lack of posterior segment
involvement, and use of TNF inhibitors (OR 6.24; 95%
CI 2.93–13.26) all as being positively correlated with
control of inflammation. Use of cyclosporine (CsA), in
contrast, was negatively correlated with uveitis control
(OR 0.26; 95% CI 0.079–0.86). These findings support an
expert panel recommendation that TNF inhibitors
should be considered second-line therapy in JIA.67
They also appear to reflect a general trend among uvei-
tis specialists away from the use of CsA.68,69 Younger
age at onset and posterior segment involvement were
also positively correlated with the need for subsequent
surgical intervention.
Liang et al.49 described the occurrence and treat-
ment of foveal serous retinal detachment (FSRD) in
nine patients with bilateral JIA-associated uveitis. The
cohort consisted of eight girls and one boy. All sub-
jects had oligoarthritis and were ANA-positive. The
FSRD was bilateral in six (66.7%) patients (15 of 18
eyes; 83.3%). While the sample size was small, eyes
with FSRD tended to have persistent flare and
appeared to have a particularly high rate of complica-
tions, including formation of posterior synechiae
(87%), cataract (80%), and band keratopathy (60%).
The authors reported that the FSRD resolved in 14
of the 15 affected eyes with intensive immunosup-
pressive therapy.
Couto et al.50 performed a retrospective analysis of
the visual prognosis and remission rate in 35 children
(61 eyes) with chronic anterior uveitis seen in a refer-
ral clinic at the University of Buenos Aires. A total of
20 of the 35 subjects (57.2%) had JIA and the remain-
der were diagnosed with idiopathic or undifferen-
tiated uveitis. Of the patients, 29 (82.9%) had one or
more complication at presentation, including band
keratopathy (29.5%), cataract (27.8%), and posterior
synechiae (22.9%). Medical treatments included sys-
temic corticosteroids in 82%, and systemic IMT in
91%, and topical corticosteroids in all patients. In
total, 15 of the 61 eyes (24.6%) underwent one or
more surgical procedures, most commonly anterior
cataract removal with IOL placement (14.7%) or pars
plana vitrectomy/lensectomy (4.9%). Either a TNF
inhibitor or rituximab was used alone or in combina-
tion in 14 patients (40.0%). All 35 patients were fol-
lowed and treated for at least 1 year, at which point
best-corrected visual acuity (BCVA) was ≥20/40 in
72.1% and ≤20/200 in 6.6%. Uveitis remission, which
was defined in accordance with the Standardization
of Uveitis Nomenclature (SUN) criteria70 as inactive
disease for at least 3 months after discontinuing all
forms of treatment, was achieved in 2.86% of 35 fol-
lowed for at least 1 year and eight patients (22.9%)
overall – although only 16 patients were followed for
at least 5 years and only two for at least 15 years. The
authors concluded that while prolonged therapy was
usually required and complications were common in
children with both JIA-associated and idiopathic
chronic anterior uveitis, visual prognosis tended to
be good with therapy.
Wiese et al.51 from Germany evaluated the change
in inflammatory activity in 32 eyes with JIA-
Uveitis in Children and Adolescents 367
© 2016 Taylor & Francis Group, LLC
associated uveitis following two different types of
glaucoma surgery: limbus-based trabeculectomy
with mitomycin (TE; 21 eyes) or Ahmed glaucoma
valve (AGV; 11 eyes) surgery. Among the 11 eyes
that underwent AGV placement, six (54.5%) had
prior TE surgery, and three (27.3%) had prior goniot-
omy. The average time from presentation to TE sur-
gery was 13.8 ± 4.2 years, and for AGV placement 17.8
± 6.1 years—an understandable difference given the
authors’ acknowledged preference for TE and their
first incisional glaucoma surgery in such patients.
Both procedures were generally successful at lower-
ing intraocular pressure (IOP) at 2 years, with the TE
group yielding a mean IOP of 12.8 ± 6.1 mmHg, and
the AGV group 14.9 ± 6.6 mmHg. In contrast, whereas
the TE group showed reduced anterior chamber flare,
the AGV group had persistent flare. The authors sug-
gested that JIA-associated uveitis is reduced after TE,
but not following AGV surgery. To support this con-
clusion, they cite a study by Stavrou and Murray,71
which showed a similar reduction in the severity of
the inflammation, decreased number of relapses, and
reduced treatment burden in a high proportion of
eyes with uveitis following TE surgery. The mechan-
isms that might explain such improved control, and
why they would be operative following TE, but not
AGV surgery remain undefined.
Ganesh et al.52 reviewed the causes, complications,
medical and surgical management, and visual out-
comes in a cohort of 190 children and adolescents
with uveitis seen over approximately a 3-year period
at a referral center in Chennai, India. Patients were
included up to 18 years of age, with a median age of
11 years. Boys comprised 64.2% of the cohort.
Approximately half (52.1%) had anterior uveitis,
30.3% of which was bilateral. Other anatomic patterns
of uveitis included intermediate (25.8%; 59.2% bilat-
eral), posterior (14.2%; 37.0% bilateral), and panuveitis
(7.9%; 60.0% bilateral). The cause of uveitis remained
indeterminant in 37.4% of cases. Trauma (14.2%) and
JIA (11.6%) were the most commonly identifed causes
of inflammation, followed by tuberculosis (7.4%), viral
uveitis (6.3%), toxoplasmosis (4.2%), toxocariasis
(4.2%), sarcoidosis (4.2%), and Vogt–Koyanagi–
Harada (VKH) disease (3.2%). Of note, infections
accounted collectively for nearly one-quarter (23.2%)
of all cases. Topical, regional, or systemic corticoster-
oids were used in 94.7% of patients, with 5.3% not
requiring treatment at presentation. Non-
corticosteroid immunosuppressive agents were added
in 24.2% of patients. Infections were typically treated
with appropriate anti-infective therapy in conjunction
with oral corticosteroids. Cysticercosis cysts were
removed surgically in the two affected patients; one
of whom also received systemic antihelminthic therapy
to treat additional cysts. Children with ocular toxocar-
iasis were treated with corticosteroids alone. A total of
77 patients (40.5%) were observed to have a total of 90
complications, 61 at presentation and 16 over the
course of follow-up. Among the entire cohort, common
complications included cataract (40; 21.1%), band ker-
atopathy (13; 6.8%), elevated IOP (13; 6.8%), and retinal
detachment (10; 5.3%). Surgical procedures were per-
formed in 55 (28.9%) cases, with lensectomy far and
away the most common, having been performed in
83.6%—half of which were done with a posterior, or
pars plana approach. The proportion of these patients
who received IOL placement was not reported. While a
detailed analysis of visual acuity outcomes was not
reported, the authors noted that with treatment, vision
improved in about two-thirds and remained stable in
about one-quarter of cases. They concluded that a
poorer prognosis was assocated with younger age at
onset, delayed referral, and longer duration of uveitis.
Finally, Lonngi et al.53 reviewed the clinical fea-
tures at presentation in a cohort of 310 children and
adolescents (463 eyes) with uveitis seen over a 13-year
period at two referral centers in Bogotá, Colombia.
Patients were included up to 18 years of age, with a
mean age of 10.1 ± 5.3 years. Girls comprised 51.9% of
the combined cohort. Just over half (58.7%) had pos-
terior uveitis, 37.9% of which was bilateral. Other
anatomic patterns of uveitis included anterior
(14.2%; 31.8% bilateral), intermediate (16.5%; 82.4%
bilateral), and panuveitis (10.6%; 84.8% bilateral).
The cause of uveitis remained indeterminant in
34.2% of cases. Toxoplasmosis (44.9%) and toxocaria-
sis (10.3%) were the most commonly identifed causes
of inflammation, followed by trauma (3.5%), JIA
(1.9%), and VKH disease (1.0%). Together, infections
accounted collectively for over half (58.4%) of all
cases. Among the 435 eyes for which BCVA was
available at presentation, Snellen acuity measured
≥20/50 in 41.5% and ≤20/200 in 42.5%. Common
complications included chorioretinal scars (44.5%),
posterior synechiae (13.5%), retinal detachment
(9.4%), glaucoma (5.2%), cataract (4.8%), macular
edema (3.5%), and band keratoapthy (3.5%). The
authors emphasized the importance of posterior infec-
tions, particularly toxoplasmosis and toxocariasis, as
well as the high prevalence of resulting monocular
(32.6%) and binocular (6.1%) blindness, in children
and adolescents with uveitis in Columbia.
Collectively, these studies highlight the often
chronic and visually compromising course of uveitis
in children and adolescents, especially in the setting
of JIA. They also confirm the importance of identify-
ing and treating common infections, particularly in
eyes with posterior or panuveitis. In eyes with non-
infectious chronic or frequently recurrent uveitis, a
tailored, step-ladder approach to control the inflam-
mation appears to provide the best chance for good
long-term prognosis. This should involve initial short-
term use of corticosteroids, an early switch to an
368 E. T. Cunningham et al.
Ocular Immunology & Inflammation
antimetabolite, such as MTX or mycophenolate mofe-
til as first-line IMT, and the use of a TNF inhibitor,
such as adalimumab or infliximab as second-line IMT.
Prolonged topical therapy in patients with ongoing
inflammation should be avoided, as this can be asso-
ciated with the late development of severe complica-
tions, such as hypotony and phthisis. Recently
presented data from the SYCAMORE trial, a rando-
mized controlled trial of the clinical effectiveness,
safety and cost-effectiveness of adalimumab in com-
bination with MTX for the treatment of JIA-associated
uveitis, demonstrated a positive treatment effect in
favor of adalimumab plus MTX versus MTX alone—
supporting a common practice of combining a TNF
inhibitor with an antimetabolite as second-line
therapy.72,73
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